Pfizer And Allergen Merged Combined Business Management Is Revealed

The $160 billion merge of Pfizer with Allergan was completed in 2015, now the management of this singular giant company is being announced.

Pfizer Incorporation made headlines last year due to its merger with Allergan Plc., worth $160 billion, which was considered as an effort to avoid huge US taxes. The merger was successful turning the medicinal company into singular giant business.

Pfizer made an agreement in November of buying out Allergan in order to reduce the amount of taxes it was paying, which is widely known as tax inversion. Bill Meury, who was the senior vice president of the taken over Botox making company, will the group president of global specialty and consumer brands the new merged unit.

The pharmaceutical company is going to be continuing running the commercial operations dividing it into two units, established products brands and innovative products business. Geno Germano is leaving the company, who was the group president of the global innovative business of the organization. The CEO of Pfizer, Ian Read is going to remain the CEO of the merged giant pharmaceutical company, while the ex-CEO of Allergen, Brent Saunders is going to be working as the chief operating officer of the business.

The Pharma giant is bringing up a new executive structure in its merged business. Albert Bourla operates the vaccines, oncology and consumer business of the company, he will now be handling the innovative department of the organization instead. Another executive, Bill Meury will be working the innovative department of the business and many of Allergan medicine, where he used to work before the merge took place.

Another executive, John Young will run Pfizer’s established product, which he had been doing before the merge took place. The decision in changing the senior board member position does not come as a surprise when it comes to the medicinal company, it did so back in 2013. The business was divided into three different sections for inflammation, rare diseases and immunology. This division is very similar in nature to the recent division, previously John Young was given the task of operating value products group and Amy Schulman was made the head of consumer products. However Amy left the company five months after this, Bourla took her job.

This recent merge has made the work of the whole organization difficult because of the large scale that it has to operate on now. Hence the company is being divided into two segments in order to make things and the work simpler for everyone, however the role of the CEO, Ian Read remain as it was before the merge. The deal is going to properly complete by the second half of 2016, as some documentations and filings are still being processed.